基于分子标志的子宫内膜癌免疫治疗模式临床研究进展

Advances in clinical research of immunotherapy modalities for endometrial cancer based on molecular markers

  • 摘要: 子宫内膜癌发病率逐年上升,癌症负担持续加重。早期高危、局部晚期和转移的子宫内膜癌传统治疗获益有限。随着检测技术和治疗模式的多元化发展,肿瘤免疫治疗作为精准医学的重要组成部分,经过多瘤种临床实证后逐渐获得妇科肿瘤领域的重视和发掘。本文结合分子病理学技术的发展,系统回顾肿瘤免疫治疗的里程碑式进展。同时,详述免疫单药和多种新型免疫联合治疗方案患者的生存获益数据,对子宫内膜癌的免疫治疗临床应用情况和前景做一归纳。有助于妇科肿瘤医师更好了解免疫治疗的优势和局限性,谨慎选择联合用药时间、次序、种类和剂量,关注临床疗效拐点,开发兼具临床获益和规避风险的优化策略。

     

    Abstract: The incidence of endometrial cancer is increasing year by year, and its burden continues to increase. Conventional treatment for early high-risk, locally advanced, and metastatic endometrial cancers shows poor benefits. With the diversified development of detection technology and treatment mode exploration, tumor immunotherapy, as an important part of precision medicine, has gradually attracted much attention and been explored in the field of gynecological oncology after clinical demonstration of multiple tumor species. This paper reviews the progresses of tumor immunotherapy in combination with the development of molecular pathology. Meanwhile, the survival benefit data of patients with single immunotherapy and multiple novel immunotherapy regimens are analyzed, and the clinical application and prospect of immunotherapy for endometrial cancer are summarized, which is helpful for gynecologists to better understand the advantages and limitations of immunotherapy, carefully select the time, order, type and dose of combination medication, focus on the inflection point of clinical efficacy, and develop optimal strategies with clinical benefits.

     

/

返回文章
返回